Tokyo, Japan, May 2, 2024 -- Heartseed Inc. (CEO: Keiichi Fukuda), a pioneer in regenerative medicine, proudly announces that Mutsuki Takano, its longstanding Chief Financial Officer, has been recognized by "CXO Magazine" as one of the "Most Innovative CFOs from Asia to Watch in 2024". This recognition is a testament to Mr. Takano's exceptional leadership in finance and his innovative approaches to funding strategies that propel Heartseed's groundbreaking initiatives in medical science.

Mr. Takano, who has been instrumental in Heartseed's growth and strategic financial planning, has played a critical role in the company's growth and its advancements in the treatment of advanced heart failure. His efforts in securing substantial investments and managing complex financial operations have significantly contributed to Heartseed's achievements.

"Mutsuki's well-deserved recognition as one of Asia's most innovative CFOs stems from his resilience and commitment," said Keiichi Fukuda, CEO of Heartseed. "His meticulous preparation and careful consideration of various scenarios reflect his dedication to stakeholder interests, ensuring our company navigates complex challenges with strategic foresight."

Mr. Takano remarked, "I am honored by this recognition and excited to continue to be a driving force to create new medical frontier at Heartseed. Our goal to advance cardiac replacement therapy for advanced heart disease remains steadfast, and I am committed to supporting our mission through strategic financial leadership."

To read more about Mr. Takano's insights and the full CXO Magazine article, please visit here. PDF file is available from here.

About Heartseed

Heartseed Inc. was founded in 2015 to develop and commercialize cardiac remuscularization therapy developed by Professor Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo, Japan. Heartseed has proprietary technologies throughout the entire manufacturing process of the cardiomyocyte-cell product, including purification, cell delivery and iPSC production.

Heartseed announced the global collaboration and license agreement with Novo Nordisk A/S for HS-001 in June 2021. Heartseed received "Minister of Science and Technology Policy Award" at Japan Venture Awards 2021 and "Ministry of Education, Culture, Sports, Science and Technology Award" at Academic Startups 2021, and "Most Promising Pipelines Awards (iPSC)" at Asia Pacific Cell & Gene Therapy Excellence Awards 2022. For more information, visit heartseed.jp, LinkedIn and YouTube.

Contact:
Kikuo Yasui,
COO, Heartseed Inc.
Tel: +81-3-6380-1068
Email: kikuo.yasui@heartseed.jp